Court sides with Te­va over Emer­gent in gener­ic Nar­can suit

Te­va Phar­ma­ceu­ti­cals is fac­ing a dif­fi­cult road ahead, thanks to 3,500 cas­es of lit­i­ga­tion sur­round­ing its role in the US opi­oid epi­dem­ic. But the man­u­fac­tur­er got a vic­to­ry last week when a US ap­peals court up­held a 2020 find­ing that ruled in fa­vor of the com­pa­ny in a law­suit ac­cus­ing the gi­ant of patent vi­o­la­tions.

The law­suit deals with nasal spray Nar­can, the an­ti-over­dose drug that fea­tures the key in­gre­di­ent nalox­one. It was filed by Adapt Phar­ma, which is owned by its more fa­mous par­ent com­pa­ny Emer­gent BioSo­lu­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER